AmpliPhi Biosciences

Activities: Analysis Pharmaceutical

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Finance

AmpliPhi Biosciences establishes Scientific Advisory Board and appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman

AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board (SAB) and the appointment of Timothy K. Lu, M.D., Ph.D., as Chairman of the SAB
Regulatory

AmpliPhi Biosciences granted SME status by European Medicines Agency

AmpliPhi's product development programmes target infections that are often resistant to existing antibiotic treatments
Finance

AmpliPhi acquires key bacteriophage assets from UK-based Novolytics

Acquired assets will broaden AmpliPhi’s IP portfolio and speed the development of phage therapies
Research & Development

AmpliPhi Biosciences appoints Alexander Gaidamaka as Vice President of CMC

Will oversee the compliant manufacture and quality assurance of phage-based therapeutics
Manufacturing

AmpliPhi's bacteriophage manufacturing facility receives cGMP certification

First cGMP-certified manufacturing facility commissioned to manufacture bacteriophage products for human use
Manufacturing

AmpliPhi’s bacteriophage manufacturing site receives cGMP certification

First cGMP facility commissioned to manufacture bacteriophage products for human use
Research & Development

Bacteria-eating viruses could aid battle against superbugs

University of Leicester team licenses technology to AmpliPhi, a pioneer in developing phage-based therapeutics
Subscribe now